The potential driving role of tau in epilepsy is important to understand, particularly given that recent experimental studies suggest that reduction of tau using antisense oligonucleotides could be a potential therapeutic option for epilepsy [44], an approach that was recently shown to be safe in human clinical trials for AD [36]. This evidence concerns the gene MAPT and epilepsy.